# Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Study · id `cardio:ct-nct06246799` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06246799](<https://clinicaltrials.gov/study/NCT06246799>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06246799

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 256 participants.

## Technical summary

Registry record NCT06246799. Randomized; no masking; primary purpose other. Start 2024-11-07 (actual); primary completion 2029-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 3
- Enrolled: 256 participants (planned count; ClinicalTrials.gov record NCT06246799, source copy `cardio:ctgov-nct06246799-2026-03-10`, retrieved 2026-10-26)
- Started: 2024-11-07 (actual) (ClinicalTrials.gov record NCT06246799, source copy `cardio:ctgov-nct06246799-2026-03-10`, retrieved 2026-10-26)
- Primary completion: 2029-04-30 (anticipated) (ClinicalTrials.gov record NCT06246799, source copy `cardio:ctgov-nct06246799-2026-03-10`, retrieved 2026-10-26)
- Completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT06246799, source copy `cardio:ctgov-nct06246799-2026-03-10`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06246799, source copy `cardio:ctgov-nct06246799-2026-03-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06246799-2026-03-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
- Condition: Type 2 Diabetes (Adult Onset)
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Pioglitazone
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Metformin HCI XR
- Lead sponsor: The University of Texas Health Science Center at San Antonio
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: The University of Texas Health Science Center at San Antonio (`cardio:org-the-university-of-texas-health-science-center-at-san-antonio`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: ecfc2f101d8b3a07d1370a47cd2cc3cedee533c5f118c39a3c49768051942160
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
